- Home
- ZVIA vs PRQR Comparison
ZVIA vs PRQR Comparison
Compare ZVIA & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVIA
- PRQR
- Stock Information
- Founded
- ZVIA 2007
- PRQR 2012
- Country
- ZVIA United States
- PRQR Netherlands
- Employees
- ZVIA N/A
- PRQR N/A
- Industry
- ZVIA Beverages (Production/Distribution)
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- ZVIA Consumer Staples
- PRQR Health Care
- Exchange
- ZVIA Nasdaq
- PRQR Nasdaq
- Market Cap
- ZVIA 227.3M
- PRQR 244.4M
- IPO Year
- ZVIA 2021
- PRQR 2014
- Fundamental
- Price
- ZVIA $2.92
- PRQR $2.05
- Analyst Decision
- ZVIA Buy
- PRQR Strong Buy
- Analyst Count
- ZVIA 4
- PRQR 8
- Target Price
- ZVIA $4.61
- PRQR $8.88
- AVG Volume (30 Days)
- ZVIA 711.9K
- PRQR 246.5K
- Earning Date
- ZVIA 08-06-2025
- PRQR 08-07-2025
- Dividend Yield
- ZVIA N/A
- PRQR N/A
- EPS Growth
- ZVIA N/A
- PRQR N/A
- EPS
- ZVIA N/A
- PRQR N/A
- Revenue
- ZVIA $158,371,000.00
- PRQR $20,129,184.00
- Revenue This Year
- ZVIA $5.72
- PRQR N/A
- Revenue Next Year
- ZVIA $6.83
- PRQR N/A
- P/E Ratio
- ZVIA N/A
- PRQR N/A
- Revenue Growth
- ZVIA N/A
- PRQR 8.65
- 52 Week Low
- ZVIA $0.90
- PRQR $1.07
- 52 Week High
- ZVIA $4.99
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- ZVIA 41.60
- PRQR 47.39
- Support Level
- ZVIA $2.84
- PRQR $1.80
- Resistance Level
- ZVIA $3.63
- PRQR $2.09
- Average True Range (ATR)
- ZVIA 0.23
- PRQR 0.14
- MACD
- ZVIA -0.04
- PRQR -0.02
- Stochastic Oscillator
- ZVIA 10.15
- PRQR 46.21
About ZVIA Zevia PBC
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.